Adagene Inc. ADR (ADAG)
NASDAQ: ADAGHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
ADAG stock chart
Technical analysisKey statistics
All statistics- Market cap
- $118.17M
- EPS (TTM)
- -$0.37
- Dividend yield
- None
- 52-week range
- 1.27 – 4.85
- Day range
- 1.35 – 2.05
- Volume / Avg
- 1.37M / 348.81K
- Beta
- —
- Shares outstanding
- 67.14M
52-week range
ADAG stock today
Shares of Adagene (ADAG) finished lower on Nov 20 at $1.76, a drop of 12.44% or $0.25 per share, versus the S&P 500's 3.70% decline. Volume was 3.9x the average at 1.37M shares, a sign of unusually heavy trading. Shares are 63.7% below their 52-week high of $4.85, set on Jul 1, 2026 and 38.9% above the 52-week low of $1.27, near the bottom of the past year's range.
ADAG is down 6.9% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 2.2%. Adagene has posted a net loss over the last twelve months (EPS of -$0.37), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Adagene
Company profileAdagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People's Republic of China. Its lead product candidate is the ADG126, a masked fully-human anti-CTLA-4 mAb which is in phase 1b/2 clinical development for the treatment of cancer. The company also develops ADG116, a fully human anti-CTLA-4 antibody generated using NEObody technology, which is in phase 1b/2 clinical trials to treat advanced/metastatic solid tumors; ADG206, which is in phase 1 clinical development to treat advanced metastatic solid tumors; ADG104, anti-PD-L1 monoclonal antibody which is in phase 2 clinical development; and ADG125, a novel anti-CSF-1R mAb which is in Phase 2 clinical development.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Peter P. Luo Ph.D.
- Headquarters
- Suzhou
- Employees
- 128
- IPO year
- 2021
- Website
- adagene.com
Financial highlights
Full financialsIn fiscal 2025, Adagene generated $7.7 million in revenue, up 7332.8% from fiscal 2024. Adagene reported a net loss of $17.6 million, compared with a loss of $33.4 million a year earlier. Operating margin was -279.5%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $7.67M | $103.20K | $18.11M | $9.29M | $10.18M |
| Growth | +7332.76% | -99.43% | +94.90% | -8.67% | +1351.71% |
| Net income | $-17.61M | $-33.42M | $-18.95M | $-79.97M | $-73.18M |
| EPS (diluted) | $-0.30 | $-0.59 | $-0.35 | $-1.48 | $-1.46 |
Analyst forecast
ForecastConsensus (6 analysts)
none
Avg. price target
$9.91+463.07%
- Strong buy 0
- Buy 6
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
ADAG news
All ADAG news- Adagene Inc. Announces First Patient Dosed in Phase 1 Study of ADG138Nasdaq
- Biotech Stocks On The Rise - AKAN +88%, CUE +49%, ADAG +24%, ANTX +23%, NRXP +10%NasdaqADAG, AKAN, ANTX, CUE
- Adagene and City of Hope Open Clinical Trial to Test New Therapy for Patients with Hard-to-Treat Colorectal CancerNasdaq
- Adagene and City of Hope Open Clinical Trial to Test New Therapy for Patients with Hard-to-Treat Colorectal CancerGlobeNewswire
- Adagene Inc. Announces Completion of Phase 2 Enrollment of Muzastotug and Expected US$8.0 million Second Closing of Sanofi InvestmentNasdaq
- Adagene to Participate in the Guggenheim Securities 3rd Annual Healthcare Innovation ConferenceGlobeNewswire
Adagene peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| MSLESatellos Bioscience Inc. | 5.68 | -2.07% | $120.51M | vs ADAG |
| OKUROnKure Therapeutics Inc. Class A | 2.70 | -2.17% | $111.21M | vs ADAG |
| MGNXMacroGenics Inc. | 1.96 | -1.01% | $125.26M | vs ADAG |
| IMUXImmunic Inc. | 6.99 | -5.41% | $111.01M | vs ADAG |
| MENSJyong Biotech Ltd. | 1.45 | -17.14% | $110.24M | vs ADAG |
| SPRBSpruce Biosciences Inc. | 38.00 | -6.15% | $109.21M | vs ADAG |
| BGMBGM Group Ltd. Class A | 8.13 | 0.00% | $108.57M | vs ADAG |
| SIONSionna Therapeutics Inc. | 2.83 | -4.88% | $127.79M | vs ADAG |
Indexes, lists and sector
Adagene stock FAQ
What is Adagene's stock price today?
ADAG last traded at $1.76 as of Nov 20, 4:00 PM EST, down 12.44% on the day. Prices are delayed at least 15 minutes.
Who is Adagene's CEO?
Dr. Peter P. Luo Ph.D. is the chief executive officer of Adagene Inc. ADR, which has about 128 employees.
What is the ADAG 52-week high?
The 52-week high for ADAG is $4.85 and the 52-week low is $1.27. The stock is currently 63.7% below its high.